Fredrik J. Eliasson - 03 Oct 2022 Form 4 Insider Report for Change Healthcare Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 Oct 2022, 16:31:42 UTC
Prior SEC filing
03 Jun 2022
Next SEC filing
26 Oct 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Robert Zachary Beasley, as Attorney-in-Fact

Key filing fact

Fredrik J. Eliasson filed Form 4 for Change Healthcare Inc. on 05 Oct 2022.

Key facts

  • This page summarizes Fredrik J. Eliasson's Form 4 filing for Change Healthcare Inc..
  • 7 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 05 Oct 2022, 16:31.

Change

  • Previous filing in this sequence was filed on 03 Jun 2022.
  • Current net transaction value: -$9,147,378.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHNG transaction

Common Stock

Disposed to Issuer

Transaction value
$5,542,378
Shares
-215,238
Change %
-36%
Price
$25.75
Shares after
380,557
Date
03 Oct 2022
Ownership
Direct
Footnotes
F1
CHNG transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-380,557
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Footnotes
F2
CHNG transaction

Common Stock

Award

Transaction value
Shares
+119,309
Change %
Price
Shares after
119,309
Date
03 Oct 2022
Ownership
Direct
Footnotes
F3
CHNG transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-119,309
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Footnotes
F3
CHNG transaction

Common Stock

Disposed to Issuer

Transaction value
$3,605,000
Shares
-140,000
Change %
-100%
Price
$25.75
Shares after
0
Date
03 Oct 2022
Ownership
See footnote
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHNG transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-695,200
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
695,200
Exercise price
$18.99
Footnotes
F5, F6
CHNG transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-695,200
Change %
-100%
Price
Shares after
0
Date
03 Oct 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
695,200
Exercise price
$18.99
Footnotes
F5, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Fredrik J. Eliasson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 7 footnotes

Footnote F1

On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash (the "Merger Consideration"), without interest and less any applicable holding tax.

Footnote F2

Pursuant to the Merger Agreement, outstanding restricted stock units ("RSUs") of the Issuer were automatically converted into UnitedHealth Group RSUs calculated by taking the Merger Consideration and dividing it by the volume weighted average of the closing sale price per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio") and continue to be subject to the same terms and conditions (including vesting and settlement terms) as were applicable to the Issuer RSUs.

Footnote F3

Reflects performance based restricted stock units ("PSUs") granted on October 29, 2020 which were originally scheduled to vest based on the achievement of certain performance criteria. Pursuant to the Merger Agreement, PSUs of the Issuer were automatically converted into time-vesting UnitedHealth Group RSUs, with the number of shares of UnitedHealth Group common stock subject to the UnitedHealth Group RSUs equal to (i) the number of shares of Common Stock underlying the Issuer PSUs based on target performance multiplied by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group RSUs will continue to be subject to the same terms and conditions as were applicable to the Issuer PSUs, and will vest on June 17, 2023.

Footnote F4

Reflects securities held by a trust, of which the Reporting Person and his spouse are trustees.

Footnote F5

In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) the Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option.

Footnote F6

These options vest in three equal annual installments commencing on June 30, 2022.

Footnote F7

These options are fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .